Viking Therapeutics, Inc. (VKTX) intrinsic value & 10-year financials
Viking Therapeutics, Inc. (VKTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -62.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $25.17
- Market cap
- $2.8B
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -62.1%
- Free cash flow (FY2025)
- —
VKTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$359.6M | -$3.19 | — | — | -59.3% |
| FY2024 | $0 | -$110.0M | -$1.01 | — | — | -26.3% |
| FY2023 | $0 | -$85.9M | -$0.91 | — | — | -49.9% |
| FY2022 | $0 | -$68.9M | -$0.90 | — | — | -64.0% |
| FY2021 | $0 | -$55.0M | -$0.71 | — | — | -25.9% |
| FY2020 | $0 | -$39.5M | — | — | — | -17.6% |
| FY2019 | $0 | -$25.8M | — | — | — | -12.1% |
| FY2018 | $0 | -$22.1M | — | — | — | -16.8% |
| FY2017 | $0 | -$20.6M | — | — | — | -177.3% |
| FY2016 | $0 | -$14.7M | — | — | — | -172.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Viking Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Viking Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -27.5% ROIC.
Viking Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Viking Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.